We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-0.93%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.68B
AUM Growth
-$472M
Cap. Flow
-$289M
Cap. Flow %
-10.8%
Top 10 Hldgs %
51.96%
Holding
86
New
15
Increased
18
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$97.1M
2
DVAX
Dynavax Technologies
DVAX
+$63.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$56M
4
HRMY icon
Harmony Biosciences
HRMY
+$49.8M
5
IMVT icon
Immunovant
IMVT
+$46.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$198M
2
NTLA icon
Intellia Therapeutics
NTLA
+$102M
3
ALKS icon
Alkermes
ALKS
+$98M
4
VRNA
Verona Pharma
VRNA
+$87.5M
5
AXSM icon
Axsome Therapeutics
AXSM
+$77M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTX icon
51
Context Therapeutics
CNTX
$55.1M
$7.79M 0.29%
7,419,355
– –
ALLK
52
DELISTED
Allakos
ALLK
$6.9M 0.26%
5,704,282
+704,282
+14% +$740K
XENE icon
53
Xenon Pharmaceuticals
XENE
$6.06B
$6.63M 0.25%
+169,132
New +$6.99M
AVTX icon
54
Avalo Therapeutics
AVTX
$965M
$6.44M 0.24%
867,000
-100,000
-10% -$1.07M
INO icon
55
Inovio Pharmaceuticals
INO
$55.7M
$5.71M 0.21%
3,119,162
+1,314,796
+73% +$5.82M
RGLS
56
DELISTED
Regulus Therapeutics
RGLS
$5.15M 0.19%
3,262,564
– –
SYRE icon
57
Spyre Therapeutics
SYRE
$8.54B
$5.1M 0.19%
219,015
-780,985
-78% -$22.9M
IVVD icon
58
Invivyd
IVVD
$158M
$4.74M 0.18%
10,689,603
-264,334
-2% -$206K
OKUR
59
OnKure Therapeutics
OKUR
$154M
$4.51M 0.17%
+523,989
New +$7.93M
FDMT icon
60
4D Molecular Therapeutics
FDMT
$532M
$3.4M 0.13%
609,900
-3,486,552
-85% -$27.4M
CLYM
61
Climb Bio
CLYM
$681M
$1.87M 0.07%
1,040,115
-1,129,028
-52% -$4.09M
NKTR icon
62
Nektar Therapeutics
NKTR
$2.39B
$1.84M 0.07%
131,733
-929,777
-88% -$16.4M
FLNA
63
PUT
Filana Therapeutics
FLNA
$48.8M
$1.18M 0.04%
+500,000
New +$8.78M
ALEC icon
64
Alector
ALEC
$168M
– –
-4,631,998
Closed -$21.6M
ALKS icon
65
Alkermes
ALKS
$8.22B
– –
-3,500,000
Closed -$98M
APGE icon
66
Apogee Therapeutics
APGE
$10.1B
– –
-1,000,000
Closed -$58.7M
ARGX icon
67
argenx
ARGX
$53.4B
– –
-365,000
Closed -$198M
AXSM icon
68
CALL
Axsome Therapeutics
AXSM
$11.2B
– –
-200,000
Closed -$18M
AXSM icon
69
Axsome Therapeutics
AXSM
$11.2B
– –
-857,219
Closed -$77M
EDIT icon
70
Editas Medicine
EDIT
$396M
– –
-4,900,334
Closed -$16.7M
FATE icon
71
Fate Therapeutics
FATE
$286M
– –
-5,572,607
Closed -$19.5M
KURA icon
72
Kura Oncology
KURA
$800M
– –
-1,963,505
Closed -$38.4M
KYMR icon
73
Kymera Therapeutics
KYMR
$8.51B
– –
-600,326
Closed -$28.4M
NTLA icon
74
Intellia Therapeutics
NTLA
$1.49B
– –
-4,950,000
Closed -$102M
PRTA icon
75
Prothena Corp
PRTA
$425M
– –
-140,000
Closed -$2.34M
1 2
3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Deep Track Capital held 86 positions worth $2.68B, down 15% from $3.15B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital withdrew a net $289M in Q4 2024, closing 23 positions and reducing 20 holdings. Its most notable exit was argenx, an estimated $198M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Harmony Biosciences worth $49.9M.

  • Deep Track Capital's largest Q4 2024 buy was Harmony Biosciences: 1,450,000 shares worth $49.9M.
  • Deep Track Capital added most to Cytokinetics in Q4 2024, an estimated $97.1M increase.
  • Deep Track Capital's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $87.5M.
  • Deep Track Capital fully exited argenx in Q4 2024, selling an estimated $198M.
  • Deep Track Capital's ten largest holdings make up 52% of its $2.68B portfolio in Q4 2024.
  • Deep Track Capital opened 15 new positions and closed 23 in Q4 2024.
  • Deep Track Capital's portfolio value fell 15% quarter-over-quarter to $2.68B.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.